Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups

被引：0

作者：

Marme, F. ^{[1
]}

Hilpert, F. ^{[2
]}

Welslau, M. K. ^{[3
]}

Grabowski, J. P. ^{[4
]}

Schneeweiss, A. ^{[5
]}

Hartkopf, A. D. ^{[6
]}

Becker, S. ^{[7
]}

Bauerschlag, D. ^{[8
]}

Fasching, P. A. ^{[9
]}

Brandi, C. ^{[10
]}

Rehbein, J. K. ^{[11
]}

Glowik, R. M. ^{[12
]}

Sehouli, J. ^{[4
]}

机构：

[1] Heidelberg Univ, Univ Med Ctr Mannheim, Med Fac Mannheim, Dept Gynecol Oncol, Mannheim, Germany

[2] Jerusalem Hosp Hamburg, Oncol Ctr, Hamburg, Germany

[3] Klinikum Aschaffenburg, Dept Oncol, Aschaffenburg, Germany

[4] Charite Berlin Univ Med, Dept Gynecol, European Competence Ctr Ovarian Canc, Ctr Oncol Surg, Berlin, Germany

[5] Natl Ctr Tumor Dis NCT, Gynecol Oncol, German Canc Res Ctr, Heidelberg, Germany

[6] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany

[7] Goethe Univ Frankfurt, Dept Obstet & Gynecol, Frankfurt, Germany

[8] Univ Klin Jena, Klin & Poliklin Frauenheilkunde & Fortpflanzu, Jena, Germany

[9] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany

[10] AGAPLESION Markus Hosp, Dept Gynecol, Frankfurt, Germany

[11] Schon Klin Rendsburg, Gynecol & Obstet, Rendsburg, Germany

[12] AstraZeneca GmbH, Med Affairs, Hamburg, Germany

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.842

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

781P

引用

页码：S586 / S587

页数：2

共 50 条

[1] Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study
Marme, Frederik
Hilpert, Felix
Welslau, Manfred
Grabowski, Jacek P.
Schneeweiss, Andreas
Hartkopf, Andreas D.
Bauerschlag, Dirk
Fasching, Peter A.
Brandi, Christiane
Rehbein, John-Kilian
Glowik, Regina
Sehouli, Jalid
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Sehouli, J.
Hilpert, F.
Welslau, M. K.
Grabowski, J. P.
Schneeweiss, A.
Hartkopf, A. D.
Becker, S.
Bauerschlag, D.
Fasching, P. A.
Brandi, C.
Rehbein, J-K.
Glowik, R. M.
Marme, F.
ANNALS OF ONCOLOGY, 2024, 35 : S582 - S582
[3] Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Marme, F.
Hilpert, F.
Welslau, M.
Grabowski, J. P.
Schneeweiss, A.
Hartkopf, A. D.
Becker, S.
Runnebaum, I.
Bauerschlag, D.
Fasching, P.
Brandi, C.
Rehbein, J-K.
Glowik, R.
Sehouli, J.
ANNALS OF ONCOLOGY, 2023, 34 : S535 - S536
[4] Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial
Gao, Qing-lei
Zhu, Jianqing
Zhao, Weidong
Huang, Yi
An, Ruifang
Zheng, Hong
Qu, Pengpeng
Wang, Li
Zhou, Qi
Wang, Danbo
Lou, Ge
Wang, Jing
Low, John
Kong, Beihua
Yin, Rutie
Lv, Weiguo
Liu, Jihong
Sun, Wei
Zang, Rongyu
Ma, Ding
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
Ledermann, Jonathan A.
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon J. S.
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Macpherson, Euan
Dougherty, Brian
Juergensmeier, Juliane M.
Orr, Maria
Matulonis, Ursula
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy
Matulonis, U. A.
Harter, P.
Gourley, C.
Friedlander, M.
Vergote, I. B.
Rustin, G. J. S.
Fielding, A.
Spencer, S.
Parry, D.
Ledermann, J. A.
GYNECOLOGIC ONCOLOGY, 2015, 137 : 8 - 8
[7] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Macpherson, Euan
Watkins, Claire
Carmichael, James
Matulonis, Ursula
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15): : 1382 - 1392
[8] Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Pignata, Sandro
Oza, Amit
Hall, Geoff
Pardo, Beatriz
Madry, Radoslaw
Cibula, David
Klat, Jaroslav
Montes, Ana
Glasspool, Rosalind
Colombo, Nicoletta
Pete, Imre
Herrero Ibanez, Ana
Romeo, Margarita
Ilieva, Rumyana
Timcheva, Constanta
Di Maio, Massimo
Bashir, Zahid
Taylor, Rosie
Barnicle, Alan
Clamp, Andrew
BRITISH JOURNAL OF CANCER, 2025, : 725 - 732
[9] Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Matulonis, Ursula A.
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Parry, David
Grinsted, Lynda
Ledermann, Jonathan A.
CANCER, 2016, 122 (12) : 1844 - 1852
[10] Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Ledermann, Jonathan A.
Pujade-Lauraine, Eric
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11

← 1 2 3 4 5 →